Company profile: Theralase
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies including Anti-Cancer Therapy (ACT) using light-activated photo dynamic compounds to destroy cancer cells; Cool Laser Therapy (CLT) for knee pain relief by reducing inflammation and accelerating healing; a Phase II NMIBC clinical study of TLD-1433; and Rutherrin, an intravenous combination of TLD-1433 with transferrin to target and destroy cancer cells.
Products and services
- Anti-Cancer Therapy (ACT): Theralase engineers a laser-activated, photo-dynamic system employing Photo Dynamic Compounds (PDCs) to generate Reactive Oxygen Species (ROS) upon laser activation, destroying cancer cells
- Rutherrin®: Theralase delivers an intravenous-administered assembly combining the Photo Dynamic Compound TLD-1433 with transferrin to more effectively target and destroy cancer cells
- Phase II NMIBC Clinical Study: Theralase conducts a Phase II study focusing on efficacy, duration of efficacy, and safety of TLD-1433 for treating Non-Muscle Invasive Bladder Cancer (NMIBC)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Theralase
Assertio
HQ: United States
Website
- Description: Provider of pharmaceutical therapies for pain and inflammation and oncology support, offering Cambia (diclofenac potassium) for acute pain; INDOCIN oral suspension and suppositories (indomethacin); SPRIX nasal spray (ketorolac) for short-term moderate to severe pain; Otrexup (methotrexate) injection for certain cancers and autoimmune diseases; and ROLVEDON to reduce severe neutropenia in chemotherapy patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Assertio company profile →
Valinor Pharma
HQ: United States
Website
- Description: Provider of innovative commercialization of medicines that deliver real benefit to patients and ensure simple, economical access when prescribed; offers MOVANTIK, an oral tablet medication used to treat opioid-induced constipation in adults with chronic non-cancer pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valinor Pharma company profile →
Cytogel Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical pain treatments with reduced side effects, including CYT-1010, a novel pain relief drug entering Phase 2 clinical development demonstrating reduced addiction potential and less risk of respiratory depression; endomorphins, a new class for pain management showing potential for safer, more effective options; and patented biocompatible polymer hydrogels for improved drug delivery and medical device coatings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytogel Pharma company profile →
Ivivi Technologies
HQ: United States
Website
- Description: Provider of medical technology, engaging in the design, development, and commercialization of electrotherapeutic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ivivi Technologies company profile →
Electromedical Technologies
HQ: United States
Website
- Description: Provider of pain relief to improve global wellness by relieving chronic and acute pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Electromedical Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Theralase
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Theralase
2.2 - Growth funds investing in similar companies to Theralase
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Theralase
4.2 - Public trading comparable groups for Theralase
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →